An Analysis of Uncertainties and Data Collection Agreements in the Cancer Drugs Fund-Reference-Cited by-同舟云学术

An Analysis of Uncertainties and Data Collection Agreements in the Cancer Drugs Fund

Published:2023-12-12 Issue: Volume: Page:
ISSN:2509-4262
Container-title:PharmacoEconomics - Open
language:en
Short-container-title:PharmacoEconomics Open

Author:

Trigg Laura A.^ORCID,Barnish Maxwell S.,Hayward Samuel,Shaw Naomi,Crathorne Louise,Groves Brad,Spoors John,Strong Thomas,Melendez-Torres G. J.,Farmer Caroline^ORCID

Funder

NHS England

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Health Policy,Pharmacology

Link

https://link.springer.com/content/pdf/10.1007/s41669-023-00460-9.pdf

Reference20 articles.

1. Dabbous M, Chachoua L, Caban A, Toumi M. Managed entry agreements: policy analysis from the European perspective. Value in Health. 2020;23(4):425–33.

2. National Health Service England. Appraisal and Funding of Caner Drugs from July 2016 (including the new Cancer Drug Fund). A new deal for patient, taxpayers and industry. 08/07/2016 2016. [Online]. https://www.england.nhs.uk/wp-content/uploads/2013/04/cdf-sop.pdf. Accessed 09 Oct 2022.

3. Wood EM, Hughes DA. The new and non-transparent Cancer Drugs Fund. Pharmacoeconomics. 2020;38(1):1–4.

4. National Institute of Health and Care Excellence. The Innovative Medicines Fund Principles. Accessed 11 Nov 2022.

5. Bril A, Canet E. The innovative medicine initiative (IMI). Médecine/Sciences M/S. 2008;24(10):885–90.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment Effect Waning Assumptions: A Review of National Institute of Health and Care Excellence Technology Appraisals;Value in Health;2024-08